Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1

Interventions

Specimen Handling 280Magnetic Resonance Spectroscopy 233pembrolizumab 220Carboplatin 180Cisplatin 146Biopsy 146Cyclophosphamide 138Paclitaxel 128Nivolumab 118Bevacizumab 106Gemcitabine 105Radiotherapy 90Dexamethasone 83Pemetrexed 79fludarabine 74Docetaxel 74atezolizumab 73Fluorouracil 73Doxorubicin 73Radiation 72Leucovorin 68Rituximab 66Oxaliplatin 64venetoclax 60Prednisone 60durvalumab 58Cetuximab 56Vincristine 55Etoposide 54Lenalidomide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
LY3295668 erbumine × 30 days × Clear all
NCT05017025 2026-05-20

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
32 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡